OTC: JWCTF - JW (Cayman) Therapeutics Co. Ltd

Yield per half year: -36.47%
Dividend yield: 0%
Sector: Healthcare

Share chart JW (Cayman) Therapeutics Co. Ltd

Extended chart Simple chart
Financial Markets by TradingView

About JW (Cayman) Therapeutics Co. Ltd

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People's Republic of China. It offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers.

more details
The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета cny
Сайт https://www.jwtherapeutics.com
Цена ао 0.162
Change price per day: -0% (0.162)
Change price per week: -0% (0.162)
Change price per month: -0% (0.162)
Change price per 3 month: -0% (0.162)
Change price per half year: -36.47% (0.255)
Change price per year: -46% (0.3)
Change price per 3 year: -79.15% (0.777)
Change price per year to date: +0.3717% (0.1614)
All parameters

Underestimation

Title Value Grade
P/S 4.52 3
P/BV 0.4665 10
P/E 0 0
EV/EBITDA -0.2077 0
Total: 5.38

Efficiency

Title Value Grade
ROA, % -35.79 0
ROE, % -45.61 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.588 10
Total: 9.6

Growth impulse

Title Value Grade
Yield Revenue, % 3070.82 10
Yield Ebitda, % 108.61 10
Yield EPS, % 9.47 2
Total: 6.2
More

Institutions Volume Share, %
DFA Emerging Markets Small Cap Series 467500 0.11
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 336309 0.08
DFA Emerging Markets Core Equity Portfolio 98500 0.02
Dimensional ETF Tr-Dimensional Emerging Markets Core Equity 2 ETF 95500 0.02
SPDR (R) Idx Shares-SPDR (R) S&P (R) China ETF 76500 0.02
Dimensional ETF Tr-Dimensional World ex U.S. Core Equity 2 ETF 69500 0.02
DFA Investment Dimensions-World Ex U.S. Core Equity Port 55500 0.01
SPDR (R) Idx Shares-SPDR (R) Emerging Markets Small Cap ETF 42350 0.01
DFA Investment Dimensions-DFA Emerging Markets Targeted Value Port 38000 0.01
Avantis Emerging Markets Equity ETF 36000 0.01



Head Job title Payment Year of birth
Dr. Yiping Li M.D. Co-Founder & Interim Chairman 836.74k 1964 (61 year)
Cao Xiaoping Ph.D. Senior Vice President of Tech Operations N/A
Dr. Shaun Paul Cordoba Ph.D. Senior VP & Chief Scientific Officer N/A 1980 (45 years)
Mr. Raymond J. Hage Jr. Senior Vice President of Corporate Development N/A 1968 (57 years)
Mr. Mark J. Gilbert M.D. Senior Advisor & Acting Chief Medical Officer N/A
Ms. Ka Man Ng A.C.I.S., A.C.S. Company Secretary N/A 1978 (47 years)
Mr. Qiang Ma Senior VP & Chief Commercial Officer N/A 1978 (47 years)
Ms. Yun Qin Senior Vice President of Clinical Sciences & Medical Services N/A 1982 (43 years)
Dr. Su Yang Senior Vice President Of Clinical Research & PMO N/A 1979 (46 years)
Mr. Min Liu CEO & Executive Director 1973 (52 years)

Address: China, Shanghai, Building B - open in Google maps, open in Yandex maps
Website: https://www.jwtherapeutics.com